A Research Study Looking Into Levels of the Medicine NNC0385-0434 in the Body and How Well it is Tolerated in Participants With Impaired Kidney Function Compared to Participants With Normal Kidney Function

PHASE1TerminatedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 9, 2021

Primary Completion Date

July 15, 2022

Study Completion Date

August 24, 2022

Conditions
Chronic Kidney Disease
Interventions
DRUG

NNC0385-0434 A 100 mg

All participants will receive the same dose (100 mg) of the study medicine NNC0385-0434, which will be given for 10 days in a row. Participants will get the study medicine in a tablet taken orally once-daily. The study medicine needs to be taken in the morning after overnight fasting and 30 minutes before the first meal of the day.

Trial Locations (1)

10117

Novo Nordisk Investigational Site, Berlin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY